ConvaTec Group PLC
LSE:CTEC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ConvaTec Group PLC
Capital Expenditures
ConvaTec Group PLC
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
ConvaTec Group PLC
LSE:CTEC
|
Capital Expenditures
-$185m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Abingdon Health PLC
LSE:ABDX
|
Capital Expenditures
-£346k
|
CAGR 3-Years
23%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Tristel PLC
LSE:TSTL
|
Capital Expenditures
-£1.4m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-4%
|
|
|
Inspecs Group PLC
LSE:SPEC
|
Capital Expenditures
-£2.9m
|
CAGR 3-Years
27%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Advanced Medical Solutions Group PLC
LSE:AMS
|
Capital Expenditures
-£12.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-16%
|
|
|
Rua Life Sciences PLC
LSE:RUA
|
Capital Expenditures
-£161k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ConvaTec Group PLC
Glance View
ConvaTec Group PLC is a notable player in the realm of medical products and technologies, deftly weaving its narrative within the healthcare industry. Founded in 1978, the company has steadily established itself through strategic expansion and innovation, focusing on improving the lives of patients and enhancing healthcare delivery. The company's core business revolves around four main product categories: Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Each of these sectors is backed by a robust commitment to research and development, allowing ConvaTec to deliver specialized products that cater to both specific patient needs and broader healthcare system demands. ConvaTec's financial model centers around providing essential, high-quality medical solutions that ultimately support improved patient outcomes. The company garners revenue by partnering with hospitals, healthcare providers, and direct consumer channels, ensuring its products reach where they are most needed. With a global footprint spanning multiple continents, ConvaTec not only distributes its products widely but also adapts its strategy to meet the nuanced requirements of diverse markets. By aligning itself closely with caregivers and leveraging cutting-edge technology, the company maintains a sustainable economic engine through both recurring sales from consumables and long-term relationships with its institutional clients.
See Also
What is ConvaTec Group PLC's Capital Expenditures?
Capital Expenditures
-185m
USD
Based on the financial report for Dec 31, 2025, ConvaTec Group PLC's Capital Expenditures amounts to -185m USD.
What is ConvaTec Group PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-17%
Over the last year, the Capital Expenditures growth was -52%. The average annual Capital Expenditures growth rates for ConvaTec Group PLC have been -9% over the past three years , -17% over the past five years .